Annals of Oncology

(ISSN: 0923-7534, 1569-8041)

Subscribe Submit

Articles Available on Medscape

 
 

Table of Contents

From Annals of Oncology

2020 - 31 (8)

  • Corrigendum to "Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial": Annals of Oncology 2012; 23: 1818-1825. 
  • Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87. 
  • Reply to the Letter to the Editor 'Germline-somatic fluidity in guiding patient care. Reply to the Letter to the Editor "Choice of control tissue impacts designation of germline variants in a cohort of papillary thyroid carcinoma patients" by J. C. Rubinstein et al.' by E. Hahn & G. S. Charames. 
  • Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. 
  • Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. 
  • Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel. 
  • Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. 
 
 

Journal Information

About the Publication: Annals of Oncology, the journal of the European Society of Medical Oncology, is a multidisciplinary journal that publishes articles addressing medical oncology, surgery, radiotherapy, paediatric oncology, basic research and the comprehensive management of patients with malignant diseases.